Skip to content
Clinical Trials – home

Suomen Terveystalo Oy

Verifiedinfo

Finland Jaakonkatu 3 A, 00100 Turku, Finland

  • 9 trials recruiting
  • Narcolepsy · Migraine · Dementia Alzheimer's type
  • Adults and children

About Specializations

Suomen Terveystalo Oy in Turku, Finland specialises in clinical trials of conditions such as Narcolepsy, Migraine, Dementia Alzheimer's type, Coeliac disease, and other specialisations. This site conducts important research.

Main research areas of the site

Cardiovascular Diseases

At Suomen Terveystalo Oy in Turku, clinical trials in cardiovascular diseases focus on major conditions such as atherosclerotic cardiovascular disease, heart failure, and hypertension. These studies are designed to test new treatment options and help reduce the risk of serious events like heart attack, stroke, and cardiovascular death.

  • Preventing major cardiovascular events in people with established or high-risk disease
  • Studying therapies for heart failure with preserved or mildly reduced ejection fraction
  • Evaluating treatments for type 2 diabetes combined with cardiovascular risk
  • Assessing therapies targeting elevated lipoprotein(a) and lipid-related risk

This area reflects a strong emphasis on improving long-term outcomes for patients with complex cardiometabolic disease.

Neurology and Mental Health

Research in nervous system diseases and psychiatry includes studies on migraine, chronic migraine, insomnia disorder, and generalized anxiety disorder. These trials aim to improve symptom control, support prevention, and evaluate how well new therapies work for people whose current treatment options have been limited.

  • Testing treatments for migraine attacks and migraine prevention
  • Evaluating care for chronic migraine in adolescents and adults
  • Studying therapies for insomnia disorder
  • Assessing treatment options for generalized anxiety disorder

The research portfolio at Terveystalo Turku shows a clear interest in conditions that can strongly affect daily functioning and quality of life.

Respiratory and Allergy Research

Trials in respiratory tract diseases and immune system diseases address chronic obstructive pulmonary disease and birch pollen-induced allergic rhinoconjunctivitis. The main purpose is to explore better ways to control symptoms, reduce flare-ups, and improve breathing and comfort for patients with chronic or seasonal disease.

  • Evaluating new approaches for COPD symptom control and exacerbation reduction
  • Studying treatment options for allergic rhinoconjunctivitis caused by birch pollen
  • Looking at ways to improve respiratory outcomes in people with ongoing lung disease
  • Testing therapies that may reduce reliance on rescue medication and standard care

These studies combine allergy and lung health research with a practical focus on everyday symptom relief.

Digestive and Metabolic Disorders

The site also supports trials in digestive system diseases and nutritional and metabolic diseases, including celiac disease and type 2 diabetes. This research is aimed at improving disease control, easing persistent symptoms, and examining new treatment strategies for people managing long-term metabolic or gastrointestinal conditions.

  • Assessing therapies for persistent symptoms in celiac disease
  • Studying treatment approaches for type 2 diabetes linked with cardiovascular risk
  • Exploring ways to improve overall disease management in chronic metabolic illness
  • Evaluating options that may help patients despite standard dietary or medical care

This area highlights research that connects digestive health with broader metabolic wellbeing.

Viral Prevention and Immunization

Trials in virus diseases at the Suomen Terveystalo Oy site include work related to influenza immunisation. The goal is to evaluate vaccine performance and support better protection against seasonal infection, especially in older adults.

  • Assessing immune response to influenza vaccines
  • Supporting prevention of seasonal viral illness in older populations
  • Studying vaccination as a public health tool for reducing infection burden
  • Comparing how well different immunization approaches protect against flu

This research reflects a preventive medicine focus within the site’s broader clinical trial activity.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Jaakonkatu 3 A00100 TurkuFinland
Recruiting now
9 trials
Conditions studied
22
Partner status
Verified

More sites in TurkuFinland

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

33 clinical trials

Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Azd5004
  • Sponsor:AstraZeneca AB
Countries:FinlandFinland
  • Participants:0–17 years · 18–64 years · Healthy volunteers
  • Substances:DROSPIRENONE
  • Sponsor:Chemo Research S.L.

Narcolepsy

Recruiting
Investigational
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Alks 2680
  • Sponsor:Alkermes Inc.
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Bi 690517
  • Sponsor:Boehringer Ingelheim Espana S.A.

Narcolepsy

Recruiting
Investigational
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:N-{(2S,3R)-4,4-Difluoro-1-(2-Hydroxy-2-Methylpropanoyl)-2-[(2,3',5'-Trifluoro[1,1'-Biphenyl]-3-Yl)Methyl]Pyrrolidin-3-Yl}Ethanesulfonamide
  • Sponsor:Takeda Development Center Americas Inc.

Coeliac disease

Recruiting
Investigational
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Methyl (E,6S)-7-[[1-[2-(2-Ethylbutylamino)-2-Oxoethyl]-2-Oxopyridin-3-Yl]Amino]-6-[(3-Methylimidazole-4-Carbonyl)Amino]-7-Oxohept-2-Enoate
  • Sponsor:Dr. Falk Pharma GmbH
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Budesonide
  • Sponsor:AstraZeneca AB
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Trospium Chloride
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Sponsor:Sanofi Vaccines US Inc.

Narcolepsy

Not yet recruiting
Investigational
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:N-{(2S,3R)-4,4-Difluoro-1-(2-Hydroxy-2-Methylpropanoyl)-2-[(2,3',5'-Trifluoro[1,1'-Biphenyl]-3-Yl)Methyl]Pyrrolidin-3-Yl}Ethanesulfonamide
  • Sponsor:Takeda Development Center Americas Inc.
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Sponsor:Amgen Inc.
Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.